Lurata 40 Tablet contains Lurasidone 40mg, an atypical antipsychotic indicated for the treatment of schizophrenia and bipolar depression. Lurasidone exerts its therapeutic effects primarily through antagonism of dopamine D2 and serotonin 5-HT2A receptors, contributing to the modulation of neurotransmitter activity implicated in psychotic and mood disorders. This medication is prescribed to alleviate symptoms such as hallucinations, delusions, mood swings, and cognitive disturbances associated with these conditions. Lurata 40 is administered orally, with dosing individualized based on clinical response and tolerability. Common adverse effects may include nausea, somnolence, akathisia, and extrapyramidal symptoms, while serious but less frequent risks involve metabolic changes, tardive dyskinesia, and neuroleptic malignant syndrome. Regular monitoring of metabolic parameters, including blood glucose and lipid profiles, is recommended during treatment. Caution is advised in patients with a history of cardiovascular disease, seizures, or hepatic impairment. Lurata 40 should not be discontinued abruptly to avoid withdrawal symptoms or relapse. It is contraindicated in individuals with hypersensitivity to Lurasidone or its excipients. Use during pregnancy and lactation should be carefully considered against potential risks. Overall, Lurata 40 Tablet provides an effective option for managing schizophrenia and bipolar depression under medical supervision.